By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Oncology. According to news reporting out of Lund, Sweden, by NewsRx editors, research stated, "Irreversible electroporation (IRE) is a local tumor treatment. Thin needles are placed percutaneously around the tumor under ultrasound guidance."
Our news journalists obtained a quote from the research from Lund University, "Short pulses of direct current sent through the tissue irreversibly increase cell membrane permeability leading to cell death. We report a phase I study assessing the safety of ultrasound guided percutaneous IRE in patients with localized pancreatic cancer (LPC). Five patients (three males) with LPC, judged unsuitable for surgery, chemotherapy, or non-resectable after standard oncological treatment, were treated with IRE. The treatment was given under general anesthesia with muscle relaxation. No serious treatment-related adverse events were observed. There was no 30-day mortality. One patient went on to laparotomy and had a R0 pancreaticoduodenectomy with portal vein resection. Six months after the treatment, two patients had no signs of recurrence on computed tomography or contrast-enhanced ultrasound."
According to the news editors, the research concluded: "IRE for LPC can be safely performed percutaneously under ultrasound guidance, with promising initial results regarding efficacy."
For more information on this research see: Safety and Preliminary Efficacy of Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Localized Pancreatic Cancer. Anticancer Research, 2014;34(1A):289-293. Anticancer Research can be contacted at: Int Inst Anticancer Research, Editorial Office 1ST Km Kapandritiou-Kalamou Rd Kapandriti, PO Box 22, Athens 19014, Greece. (International Institute of Anticancer Research - www.iiar-anticancer.org/; Anticancer Research - www.iiar-anticancer.org/main.php?id=2)
Our news journalists report that additional information may be obtained by contacting C. Mansson, Lund University, Dept. of Surg, Lund, Sweden. Additional authors for this research include M. Bergenfeldt, R. Brahmstaedt, B.M. Karlson, P. Nygren and A. Nilsson (see also Oncology).
Keywords for this news article include: Lund, Drugs, Sweden, Europe, Oncology, Treatment, Chemotherapy, Gastroenterology, Pancreatic Cancer, Pancreatic Neoplasms
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC